Sheldon Sloan sold $5.6M of SYRE
Chief Medical Officer at Spyre Therapeutics, Inc.. 78,333 shares at an average of $71.50, traded May 1, 2026, filed May 1, 2026.
Score components
- +15RoleOfficer
- +25Trade size$5.6M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002038798-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2026 | MOption exercise Common Stock10b5-1 | +78,333 | $27.46 | $2.2M | 78,333 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -21,306 | $69.53 | $1.5M | 57,027 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -19,656 | $70.61 | $1.4M | 37,371 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -8,777 | $71.56 | $628k | 28,594 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -12,777 | $72.94 | $932k | 15,817 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -10,358 | $73.74 | $764k | 5,459 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -5,059 | $74.60 | $377k | 400 | May 1, 2026 |
| May 1, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $75.37 | $30k | 0 | May 1, 2026 |
| May 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -78,333 | $0.00 | $0 | 321,667 | May 1, 2026 |
Related signals
Other insiders at Spyre Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,000 shares | -26% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.6M 28,933 shares | -91% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.4M 15,000 shares | -3% | |
| 32Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,732 shares | -24% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.5M 28,399 shares | -92% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.3M 15,000 shares | -3% | |
| 40Moderate | Spyre Therapeutics, Inc. | Jeffrey W. Albers director | $2.4M 23,000 shares | -460% | |
| 23Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $717k 7,500 shares | -7% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.4M 15,000 shares | -3% | |
| 22Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $658k 7,500 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.